Tag Archives: treatment
PAPR Inhibitors May Work Against More Ovarian Cancers
PAPR inhibitors, first used in trials for women with ovarian cancer who had a mutation in the BRCA1 or BRCA2 gene, are now being used in trials for women without … Continue reading
Posted in News
Also tagged clinical trials, genetics, recurrence, Research, science, side effects
Leave a comment
Chemo Dosing Influences Drug Resistance
A mouse study showed that continuous treatment with docetaxel (Taxotere) showed greater anti-tumor effects than treating the mice once a week or once every three weeks. Additionally, treating less often … Continue reading
Posted in News
Also tagged cancer treatment, chemotherapy, Research, resistance, science
Leave a comment
Chemotherapy Drug Shortages include Taxol
Drug shortages around the country are affecting cancer patients. Recently ABC news covered the paclitaxel (brand name: Taxol) shortage. Many cite the low cost of generic drugs as the cause of … Continue reading
Drug Combination to Treat Cancer Expected to Rise
According to an article in the Wall Street Journal, combinations of drugs to treat cancer will be used more frequently in the future. Many studies presented at the 2011 annual … Continue reading
J&J withdraws application with FDA for new ovarian cancer drug
Johnson & Johnson, the owner of rights to Yondelis in the United States, has withdrawn its New Drug Application with the Food and Drug Administration for approval of the drug … Continue reading
Cost-Effective Analysis of Bevacizumab for Ovarian Cancer
A study published in the Journal of Clinical Oncology concludes that “[t]he addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective.” The study … Continue reading
Carbo/Doxil in elderly patients
BACKGROUND: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients <70 … Continue reading
Phase II Trial of Phenoxodial Complete
INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we … Continue reading
ESAs Linked to Ovarian Cancer Mortality (Medpage)
A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs … Continue reading
Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released
Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial. See the … Continue reading
Ovarian cancer in the elderly patient: are we doing enough?
INTRODUCTION: ovarian cancer is deadly and frequently affects older patients. In the next 20 years, the number of patients over 65 will double, and cancer, including ovarian cancer, will increase … Continue reading
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian … Continue reading
